Preparation method for moxifloxacin intermediate (1S, 6R)-8-benzyl-7, 9-dioxy-2, 8-diazabicyclo [4.3.0] nonane

A technology of diazabicyclo and moxifloxacin, which is applied in organic chemistry methods, chemical instruments and methods, organic racemization, etc., can solve the problems of inconvenient large-scale production, high optical purity, and low content, and achieve the reduction of raw material consumption, Effect of avoiding purification process and reducing production cost

Active Publication Date: 2012-04-11
ZHEJIANG APELOA KANGYU PHARMA +2
View PDF3 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The resolving agent that this method uses is more expensive, and consumption is big (molecular weight is big), and resolving agent is unstable under acidic conditions, is unfavorable for improving its recovery rate and causes resolving agent to account for a large proporti

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method for moxifloxacin intermediate (1S, 6R)-8-benzyl-7, 9-dioxy-2, 8-diazabicyclo [4.3.0] nonane
  • Preparation method for moxifloxacin intermediate (1S, 6R)-8-benzyl-7, 9-dioxy-2, 8-diazabicyclo [4.3.0] nonane
  • Preparation method for moxifloxacin intermediate (1S, 6R)-8-benzyl-7, 9-dioxy-2, 8-diazabicyclo [4.3.0] nonane

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0051] Example 1

[0052] 10.00g (40.94mmol) cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane in a 250ml reaction flask, add 100ml isopropyl acetate, room temperature Stir until all of it is dissolved, add 4.25g (24.54mmol) N-acetyl-L-leucine, heat up to 70-80℃ and react for 40 minutes, slowly reduce the temperature to 40℃, and crystals will precipitate, continue to cool down to 25℃, stir overnight. The next day, filter, wash the reaction flask with the filtrate, and wash the crystals with 4g×2 isopropyl acetate to obtain (1 S ,6 R )-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane·N-acetyl-L-leucine salt, wet weight 7.80g, reduced pressure at 40°C Dry, weighs 7.75g, theoretical yield is 90.69%, optical purity is 95.05% ee.

[0053] The 7.75g obtained above (1 S ,6 R )-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane·N-acetyl-L-leucine salt, recrystallized with 44g of acetonitrile, the obtained crystals are 40 Drying under reduced pressure at ℃ weighs 6.31g, the total yield ...

Example Embodiment

[0055] Example 2

[0056] (1 S ,6 R )-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane·N-acetyl-L-leucine salt 6.31g (15.11mmol) floating 15g To the methyl chloride, add 16g water and 1.5g NaHCO 3 , Stir at 31°C, after the two phases are clear, separate the organic phase, and extract the aqueous phase with 5g×2 dichloromethane. The organic phases were combined, dried with 5 g of anhydrous sodium sulfate, filtered, washed with 5 g of dichloromethane, and the obtained filtrate was recovered under reduced pressure to recover dichloromethane to obtain the product (1 S ,6 R )-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane 3.44g, [α] D 20 = -24.4?? (c=0.005, ethanol), the optical purity is 99.31%ee.

[0057] 1 HNMR (CDCl 3 , MHz) δppm: 7.23-7.34 (m, 5H), 4.62 (s, 2H), 3.79-3.81 (d, 1H), 2.79-2.85 (dd, 1H), 2.73-2.78 (m,1H), 2.61- 2.67 (m, 1H), 2.16 (br s, 1H), 1.89-1.97 (m, 1H), 1.59-1.68 (m, 1H), 1.45-1.51 (m, 2H).

[0058] 13 CNMR (CDCl 3 , MHz) δppm: 177.92, 177.76, 135.83, 128.61,...

Example Embodiment

[0059] Example 3

[0060] Method 46 Preparation (1 S ,6 R )-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane·N-acetyl-L-leucine salt 7.27g (17.41mmol) suspended in 15g toluene Medium, add 16g water and 1.6g NaHCO 3 , Stir at 30°C, after the two phases are clear, separate the organic phase, and extract the water phase with 5g×2 toluene. The organic phases were combined, dried with 5 g of anhydrous sodium sulfate, filtered, and washed with 4.5 g of toluene. The obtained filtrate was decompressed to recover toluene to obtain the product (1 S ,6 R )-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane 4.26g, optical purity: 92.63%ee.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Optical purityaaaaaaaaaa
Login to view more

Abstract

The invention discloses a preparation method for moxifloxacin intermediate (1S, 6R)-8-benzyl-7, 9-dioxy-2, 8-diazabicyclo [4.3.0] nonane. Crystallization of (1S, 6R)-8-benzyl-7, 9-dioxy-2, 8-diazabicyclo [4.3.0] nonane N-acetyl-L-leucine diastereomeric salts is formed by Cis-8-benzyl-7, 9-dioxy-2, 8-diazabicyclo [4.3.0] nonane and N-acetyl-L-leucine in a splitting solvent and dissociates in a alkaline liquid such as Na2CO3 or NaHCO3. The crystallization is extracted through an organic solvent and decompressed and concentrated through organic phases to obtain (1S, 6R)-8-benzyl-7, 9-dioxy-2, 8-diazabicyclo [4.3.0] nonane. The preparation method for moxifloxacin intermediate (1S, 6R)-8-benzyl-7, 9-dioxy-2, 8-diazabicyclo [4.3.0] nonane has low production cost and is simple and convenient to split; moreover, fussy purge process during subsequent reaction is avoided. Products of the preparation method not only have high optical purity, but also have higher content.

Description

technical field [0001] The invention relates to the technical field of production of pharmaceutical intermediates, in particular to a moxifloxacin intermediate (1 S ,6 R )-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane. Background technique [0002] Moxifloxacin is an 8-methoxyfluoroquinolone broad-spectrum antimicrobial drug indicated for the treatment of acute sinusitis, acute exacerbation of chronic bronchitis, community-acquired pneumonia in adults with respiratory infections, and skin and soft tissue infections. It was launched in Germany and the United States in 1999 and in China in 2002. The chemical name of moxifloxacin is 1-cyclopropyl-6-fluoro-8-methoxy-7-[(4a S ,7a S )-octahydro-6 H -pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquine-3-carboxylate hydrochloride. [0003] [0004] A kind of moxifloxacin intermediate (1 S ,6 R )-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane preparation method, specifically: cis-8-benzyl-7,9-dioxo -2,8-diazabicyclo[4...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D471/04C07B57/00
Inventor 戴鹏张柏林张柯华
Owner ZHEJIANG APELOA KANGYU PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products